Innovent Biologics

OverviewSuggest Edit

Innovent Biologics,Inc. is a leading biopharmaceutical company in China focused on the discovery, development and manufacturing of complex, high-end biologics for both the Asian and global markets that meet EMA and FDA/cGMP standards. Innovent has an expanding biologics pipeline focused on oncology, inflammatory diseases and ophthalmology. Innovent's strategy is to advance its internal pipeline of proprietary biologic drugs and establish in/out-licensing agreements with global pharmaceutical/biotech companies. Because of its location and emphasis on quality, Innovent is able to leverage China's cost-efficient environment without compromising its world-class quality standards.
HQFangshan Qu, CN

Latest Updates

Employees (est.) (May 2022)858(+4%)
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Innovent Biologics Office Locations

Innovent Biologics has an office in Fangshan Qu
Fangshan Qu, CN (HQ)
Dong Ping Jie
Show all (1)

Innovent Biologics Financials and Metrics

Summary Metrics

Founding Date


Innovent Biologics total Funding

$560 m

Innovent Biologics latest funding size

$150 m

Time since last funding

4 years ago

Innovent Biologics investors

Innovent Biologics's latest funding round in April 2018 was reported to be $150 m. In total, Innovent Biologics has raised $560 m
Show all financial metrics

Innovent Biologics Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Innovent Biologics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset


out of 100

CSRHub logo

Innovent Biologics Online and Social Media Presence

Embed Graph

Innovent Biologics News and Updates

Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct

Agreement combines IASO Bio and Innovent’s CAR construct, validated in clinical trials, with Sana’s in vivo and ex vivo engineered cell therapy programs Agreement combines IASO Bio and Innovent’s CAR construct, validated in clinical trials, with Sana’s in vivo and ex vivo engineered cell therapy pro…

Laekna Therapeutics and Innovent Biologics obtain IND approval for combination therapy in patients with specific types of solid tumors who have been refractory to treatment with PD-1/PD-L1 inhibitors

SHANGHAI, China and WARREN, N.J., Jan. 9, 2022 /PRNewswire/ -- Today, Laekna Therapeutics announced that the investigational new drug (IND) application of a combination therapy for the phase 1/2 clinical trial in patients with solid tumors who have been refractory to treatment with...

IASO Biotherapeutics and Innovent Biologics Announced Updated Clinical Data of BCMA CAR-T Therapy in Oral Presentation at 2021 ASH Annual Meeting

SAN JOSE and SAN FRANCISCO and NANJING, China, Dec. 12, 2021 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a clinical-stage biopharmaceutical company focused on discovering, developing, and manufacturing innovative medicines and Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a...

UNION therapeutics and Innovent Biologics enter into strategic collaboration and license agreement for orismilast, a next-generation PDE4 inhibitor for inflammatory dermatology conditions

HELLERUP, Denmark, SAN FRANCISCO and SUZHOU, China, Sept. 28, 2021 /PRNewswire/ -- UNION therapeutics A/S ('UNION'), a privately-held, multi-asset, clinical stage, pharmaceutical company focused on immunology and infectious diseases, and Innovent Biologics (HK) Limited, a subsidiary of...

Bolt Biotherapeutics and Innovent Biologics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs

REDWOOD CITY, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune system…

Innovent Biologics and AnHeart Therapeutics Jointly Announce Exclusive License Agreement for Taletrectinib in Greater China

SAN FRANCISCO and SUZHOU, China, May 31, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major...
Show more

Innovent Biologics Frequently Asked Questions

  • When was Innovent Biologics founded?

    Innovent Biologics was founded in 2011.

  • How many employees does Innovent Biologics have?

    Innovent Biologics has 858 employees.

  • Who are Innovent Biologics competitors?

    Competitors of Innovent Biologics include Roivant Sciences, Legend Biotech and ILC Therapeutics.

  • Where is Innovent Biologics headquarters?

    Innovent Biologics headquarters is located at Dong Ping Jie, Fangshan Qu.

  • Where are Innovent Biologics offices?

    Innovent Biologics has an office in Fangshan Qu.

  • How many offices does Innovent Biologics have?

    Innovent Biologics has 1 office.